Focus Equities

DexCom Presents New Data

images (8)

DexCom said Friday it will present new clinical data that shows adults with type 1 and type 2 diabetes on multiple daily injections (MDI) benefit from continuous glucose monitoring (CGM), at the American Diabetes Association’s 77th Scientific Sessions, June 9-13 in San Diego, California.

The new data is the result of combined type 1 and type 2 cohorts from the multiple daily injections and continuous glucose monitoring in diabetes study (DIaMonD) and demonstrates the impact of continuous glucose monitoring on A1C, hyperglycemia and hypoglycemia in adults with either type 1 or type 2 diabetes who choose to take multiple daily injections of insulin in lieu of other methods of insulin delivery. The study showed DexCom CGM System users achieved a 0.9% average A1C reduction after 24 weeks of regular use, compared with 0.5% in the usual care group that relied only on fingerstick blood glucose measurements. The benefits in glycemic control were seen even in study participants using CGM that had large decreases in the number of fingersticks, the company said.